Lipocine Free Cash Flow (FCF) History (LPCN)
Lipocine reported −$1.3M in free cash flow for fiscal 2024, an increase of $10.6M from the previous fiscal year, with a free cash flow margin of −11.71%.
View full Lipocine company overviewLipocine free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$1.3M | $10.6M | — | −11.71% |
| 2023 | 2023-12-31 | −$11.9M | $223,492 | — | — |
| 2022 | 2022-12-31 | −$12.1M | −$7.7M | — | −2420.53% |
| 2021 | 2021-12-31 | −$4.4M | $7.7M | — | −27.38% |
| 2018 | 2018-12-31 | −$12.1M | $4.6M | — | −2821.95% |
| 2017 | 2017-12-31 | −$16.7M | $1.6M | — | — |
| 2016 | 2016-12-31 | −$18.3M | −$3.0M | — | — |
| 2015 | 2015-12-31 | −$15.4M | $2.0M | — | — |
| 2014 | 2014-12-31 | −$17.4M | −$8.8M | — | — |
| 2013 | 2013-12-31 | −$8.6M | −$5.4M | — | — |
| 2012 | 2012-12-31 | −$3.2M | — | — | −41.39% |
Lipocine quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-12-31 | −$2.0M | −$95,826 | — | −939.68% |
| Q3 2023 | 2023-09-30 | −$2.6M | $592,142 | — | — |
| Q2 2023 | 2023-06-30 | −$3.3M | −$252,966 | — | — |
| Q1 2023 | 2023-03-31 | −$3.9M | −$19,858 | — | −7150.49% |
| Q4 2022 | 2022-12-31 | −$1.9M | $2.4M | — | — |
| Q3 2022 | 2022-09-30 | −$3.2M | $1.4M | — | — |
| Q2 2022 | 2022-06-30 | −$3.1M | $1.6M | — | −611.33% |
| Q1 2022 | 2022-03-31 | −$3.9M | −$773,448 | — | — |
| Q4 2017 | 2017-12-31 | −$4.3M | −$1.7M | — | — |
| Q3 2017 | 2017-09-30 | −$4.6M | −$516,221 | — | — |
| Q2 2017 | 2017-06-30 | −$4.7M | $496,107 | — | — |
| Q1 2017 | 2017-03-31 | −$3.1M | $3.4M | — | — |
| Q4 2016 | 2016-12-31 | −$2.5M | $364,560 | — | — |
| Q3 2016 | 2016-09-30 | −$4.0M | $1.5M | — | — |
| Q2 2016 | 2016-06-30 | −$5.2M | −$1.3M | — | — |
| Q1 2016 | 2016-03-31 | −$6.5M | −$3.5M | — | — |
| Q4 2015 | 2015-12-31 | −$2.9M | $1.1M | — | — |
| Q3 2015 | 2015-09-30 | −$5.6M | −$3.1M | — | — |
| Q2 2015 | 2015-06-30 | −$3.9M | $3.8M | — | — |
| Q1 2015 | 2015-03-31 | −$3.0M | $181,052 | — | — |
| Q4 2014 | 2014-12-31 | −$4.0M | $111,706 | — | — |
| Q3 2014 | 2014-09-30 | −$2.5M | $2.0M | — | — |
| Q2 2014 | 2014-06-30 | −$7.6M | −$7.6M | — | — |
| Q1 2014 | 2014-03-31 | −$3.2M | −$3.2M | — | — |
| Q4 2013 | 2013-12-31 | −$4.1M | — | — | — |
| Q3 2013 | 2013-09-30 | −$4.5M | — | — | — |
| Q2 2013 | 2013-06-30 | −$448 | — | — | — |
| Q1 2013 | 2013-03-31 | −$1,325 | — | — | — |
Lipocine free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$16.7M to −$1.3M, a net increase of $15.4M. Lipocine's latest reported quarter, Q4 2023, generated −$2.0M in free cash flow, a decrease of $95,826 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Lipocine filings at SEC.gov ↗